Top

Published in:

Open Access 01-12-2023 | Radiotherapy | Review

Weekly versus triweekly cisplatin treatment in patients with locally advanced nasopharyngeal cancer during concurrent chemoradiotherapy

Authors: Xin Li, Lei Li, Ruimei Sun, Jingyan Gao, Zhengfei Li, Yongyuan Xue, Lixiu Zhu, Tianrui Xu, Chuanzheng Sun, Yan Xi, Wei Xiong

Published in: European Journal of Medical Research | Issue 1/2023

Abstract

Background

For patients with locally advanced nasopharyngeal cancer (LA-NPC), concurrent chemoradiotherapy (CCRT) is the standardized treatment. However, whether a weekly or triweekly cisplatin regimen should be used during CCRT is controversial. Therefore, we conducted this meta-analysis to explore differences in the effects and toxicities of the two regimens.

Methods

We searched PubMed, Embase, and the Cochrane Library (until June 10, 2022). We evaluated overall survival (OS), distant metastasis-free survival (DMFS), locoregional recurrence–free survival (LRFS), disease-free survival (DFS) and grade ≥ 3 adverse events. The effect indices were hazard ratios (HRs) and odds ratios (ORs), and Review Manager software 5.4 (RevMan 5.4) was used for computations.

Results

We identified 7 studies in our analysis. There was no significant difference in OS (HR = 1.00, 95% CI 0.73–1.38, P = 0.99), DMFS (HR = 0.84, 95% CI 0.58–1.22, P = 0.36), LRFS (HR = 0.91, 95% CI 0.63–1.32, P = 0.62) or DFS (HR = 0.93, 95% CI 0.56–1.56; P = 0.78) between the weekly and triweekly cisplatin regimens. We found that the weekly cisplatin regimen was more likely to cause grade ≥ 3 hematological toxicity events than the triweekly cisplatin regimen. In addition, subgroup analyses revealed that patients undergoing CCRT and CCRT plus adjuvant chemotherapy (AC) had similar OS or DFS.

Conclusion

Weekly and triweekly cisplatin regimens had similar efficacy for LA-NPC. The triweekly regimen may replace the weekly regimen for LA-NPC because of lower toxicity. Larger data accumulation and more multicenter clinical trials may be needed to verify these results.

Xia WX, Lv X, Liang H, Liu GY, Sun R, Zeng Q, et al. A Randomized controlled trial comparing two different schedules for cisplatin treatment in patients with locoregionally advanced nasopharyngeal cancer. Clin Cancer Res. 2021;27(15):4186–94. https://doi.org/10.1158/1078-0432.CCR-20-4532.CrossRefPubMedPubMedCentral

Afqir S, Ismaili N, Errihani H. Concurrent chemoradiotherapy in the management of advanced nasopharyngeal carcinoma: current status. J Can Res Ther. 2009;5(1):3–7. https://doi.org/10.4103/0973-1482.48763.CrossRef

Baujat B, Audry H, Bourhis J, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys. 2006;64(1):47–56. https://doi.org/10.1016/j.ijrobp.2005.06.037.CrossRefPubMed

Wei WI, Sham JS. Present status of management of nasopharyngeal carcinoma. Expert Rev Anticancer Ther. 2001;1(1):134–41. https://doi.org/10.1586/14737140.1.1.134.CrossRefPubMed

Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005;365(9476):2041–54. https://doi.org/10.1016/S0140-6736(05)66698-6.CrossRefPubMed

Meng DF, Sun R, Peng LX, Huang YS, Yang Q, Luo DH, et al. A comparison of weekly versus 3-weekly cisplatin during concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma using intensity modulated radiation therapy: a matched study. J Cancer. 2018;9(1):92–9. https://doi.org/10.7150/jca.21357.CrossRefPubMedPubMedCentral

Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343: d5928. https://doi.org/10.1136/bmj.d5928.CrossRefPubMedPubMedCentral

Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5. https://doi.org/10.1007/s10654-010-9491-z.CrossRefPubMed

Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. https://doi.org/10.1186/1745-6215-8-16.CrossRefPubMedPubMedCentral

10.

Lee JY, Sun JM, Oh DR, Lim SH, Goo J, Lee SH, et al. Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: a multicenter randomized phase II trial (KCSG-HN10–02). Radiother Oncol. 2016;118(2):244–50. https://doi.org/10.1016/j.radonc.2015.11.030.CrossRefPubMed

11.

Zhu Q, Hu H, Tang LQ, You R, Zhao JJ, Weng DS, et al. Weekly versus triweekly cisplatin plus intensity-modulated radiotherapy in locally advanced nasopharyngeal carcinoma: a propensity score analysis with a large cohort. J Cancer. 2018;9(19):3447–55. https://doi.org/10.7150/jca.26110.CrossRefPubMedPubMedCentral

12.

Wang K, Dong J, He S, Wang X, Jiang C, Hu P, et al. Comparison of weekly and triweekly cisplatin regimens during concurrent chemoradiotherapy for nasopharyngeal carcinoma. BMC Cancer. 2019;19(1):482. https://doi.org/10.1186/s12885-019-5688-z.CrossRefPubMedPubMedCentral

13.

Gundog M, Basaran H, Bozkurt O, Eroglu C. A comparison of cisplatin cumulative dose and cisplatin schedule in patients treated with concurrent chemo-radiotherapy in nasopharyngeal carcinoma. Braz J Otorhinolaryngol. 2020;86(6):676–86. https://doi.org/10.1016/j.bjorl.2019.04.008.CrossRefPubMed

14.

Jagdis A, Laskin J, Hao D, Hay J, Wu J, Ho C. Dose delivery analysis of weekly versus 3-weekly cisplatin concurrent with radiation therapy for locally advanced nasopharyngeal carcinoma (NPC). Am J Clin Oncol. 2014;37(1):63–9. https://doi.org/10.1097/COC.0b013e31826b9b1a.CrossRefPubMed

15.

Chen QY, Wen YF, Guo L, Liu H, Huang PY, Mo HY, Li NW, Xiang YQ, Luo DH, Qiu F, Sun R, Deng MQ, Chen MY, Hua YJ, Guo X, Cao KJ, Hong MH, Qian CN, Mai HQ. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst. 2011;103(23):1761–70. https://doi.org/10.1093/jnci/djr432.CrossRefPubMed

16.

Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16:1310–7. https://doi.org/10.1200/JCO.1998.16.4.1310.CrossRefPubMed

17.

Liang ZG, Zhu XD, Zhou ZR, Qu S, Du YQ, Jiang YM. Comparison of concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of 793 patients from 5 randomized controlled trials. Asian Pac J Cancer Prev. 2012;13(11):5747–52. https://doi.org/10.7314/apjcp.2012.13.11.5747. (PMID: 23317250).CrossRefPubMed

18.

Zhang B, Li MM, Chen WH, Zhao JF, Chen WQ, Dong YH, Gong X, Chen QY, Zhang L, Mo XK, Luo XN, Tian J, Zhang SX. Association of chemoradiotherapy regimens and survival among patients with nasopharyngeal carcinoma: a systematic review and meta-analysis. JAMA Netw Open. 2019;2(10): e1913619. https://doi.org/10.1001/jamanetworkopen.2019.13619.CrossRefPubMedPubMedCentral

19.

Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC metaanalysis. Lancet Oncol. 2015;16:645–55. https://doi.org/10.1016/S1470-2045(15)70126-9.CrossRefPubMed

20.

Zhang ZJ, Shi LL, Hong XH, Xiao BY, Lin GH, Liu Q, Wang BC. A Bayesian network meta-analysis of the primary definitive therapies for locoregionally advanced nasopharyngeal carcinoma: IC+CCRT, CCRT+AC, and CCRT alone. PLoS ONE. 2022;17(3): e0265551. https://doi.org/10.1371/journal.pone.0265551.CrossRefPubMedPubMedCentral

21.

Szturz P, Wouters K, Kiyota N, Tahara M, Prabhash K, Noronha V, Castro A, Licitra L, Adelstein D, Vermorken JB. Weekly low-dose versus three-weekly high-dose cisplatin for concurrent chemoradiation in locoregionally advanced non-nasopharyngeal head and neck cancer: a systematic review and meta-analysis of aggregate data. Oncologist. 2017;22(9):1056–66. https://doi.org/10.1634/theoncologist.2017-0015.CrossRefPubMedPubMedCentral

22.

Jacinto JK, Co J, Mejia MB, Regala EE. The evidence on effectiveness of weekly vs triweekly cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC): a systematic review and meta-analysis. Br J Radiol. 2017;90(1079):20170442. https://doi.org/10.1259/bjr.20170442.CrossRefPubMedPubMedCentral

23.

Peng H, Chen L, Zhang Y, Li WF, Mao YP, Zhang F, Guo R, Liu LZ, Lin AH, Sun Y, Ma J. Prognostic value of the cumulative cisplatin dose during concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a secondary analysis of a prospective phase III clinical trial. Oncologist. 2016;21(11):1369–76. https://doi.org/10.1634/theoncologist.2016-0105.CrossRefPubMedPubMedCentral

24.

Rampino M, Ricardi U, Munoz F, Reali A, Barone C, Musu AR, Balcet V, Franco P, Grillo R, Bustreo S, et al. Concomitant adjuvant chemoradiotherapy with weekly low-dose cisplatin for high-risk squamous cell carcinoma of the head and neck: a phase II prospective trial. Clin Oncol. 2011;23(2):134–40. https://doi.org/10.1016/j.clon.2010.09.004.CrossRef

25.

Chan ATC, Hui EP, Ngan RKC, Tung SY, Cheng ACK, Ng WT, Lee VHF, Ma BBY, Cheng HC, Wong FCS, Loong HHF, Tong M, Poon DMC, Ahuja AT, King AD, Wang K, Mo F, Zee BCY, Chan KCA, Lo YMD. Analysis of plasma epstein-barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial. J Clin Oncol. 2018. https://doi.org/10.1200/JCO.2018.77.7847.CrossRefPubMedPubMedCentral

26.

Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, Sun Y, Li WX, Chen YY, Xie FY, Liang SB, Chen Y, Xu TT, Li B, Long GX, Wang SY, Zheng BM, Guo Y, Sun Y, Mao YP, Tang LL, Chen YM, Liu MZ, Ma J. Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial. Eur J Cancer. 2017;75:150–8. https://doi.org/10.1016/j.ejca.2017.01.002.CrossRefPubMed

27.

Yan M, Kumachev A, Siu LL, Chan KK. Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: a Bayesian network meta-analysis. Eur J Cancer. 2015;51(12):1570–9. https://doi.org/10.1016/j.ejca.2015.04.027.CrossRefPubMed

28.

Chen YP, Wang ZX, Chen L, Liu X, Tang LL, Mao YP, Li WF, Lin AH, Sun Y, Ma J. A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. Ann Oncol. 2015;26(1):205–11. https://doi.org/10.1093/annonc/mdu507.CrossRefPubMed

29.

Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, Sun Y, Li WX, Chen YY, Xie FY, Liang SB, Chen Y, Xu TT, Li B, Long GX, Wang SY, Zheng BM, Guo Y, Sun Y, Mao YP, Tang LL, Chen YM, Liu MZ, Ma J. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012;13(2):163–71. https://doi.org/10.1016/S1470-2045(11)70320-5.CrossRefPubMed

30.

Chen Y, Liu MZ, Liang SB, Zong JF, Mao YP, Tang LL, Guo Y, Lin AH, Zeng XF, Ma J. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. Int J Radiat Oncol Biol Phys. 2008;71(5):1356–64. https://doi.org/10.1016/j.ijrobp.2007.12.028.CrossRefPubMed

31.

Zhang MX, Li J, Shen GP, Zou X, Xu JJ, Jiang R, et al. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: a 10-year experience with a large cohort and long follow-up. Eur J Cancer. 2015;51(17):2587–95. https://doi.org/10.1016/j.ejca.2015.08.006.CrossRefPubMed

32.

Xu T, Zhou X, Shen C, Hu C. Suggestions for surveillance and radiation strategy in nasopharyngeal carcinoma treated with IMRT: based on hazard-rate and patterns of recurrence. Oral Oncol. 2018;76:61–7. https://doi.org/10.1016/j.oraloncology.2017.11.022.CrossRefPubMed

33.

Chen L, Zhang Y, Lai SZ, Li WF, Hu WH, Sun R, et al. 10-year results of therapeutic ratio by intensity-modulated radiotherapy versus two-dimensional radiotherapy in patients with nasopharyngeal carcinoma. Oncologist. 2019;24(1):e38-45. https://doi.org/10.1634/theoncologist.2017-0577.CrossRefPubMed

34.

Fountzilas G, Ciuleanu E, Bobos M, et al. Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. Ann Oncol. 2012;23(2):427–35. https://doi.org/10.1093/annonc/mdr116.CrossRefPubMed

35.

Hong RL, Hsiao CF, Ting LL, et al. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma Taiwan Cooperative Oncology Group (TCOG) 1303 Study. AnnOncol. 2018;29(9):1972–9. https://doi.org/10.1093/annonc/mdy249.CrossRef

36.

Ma J, Tang L-L, Guo R, Zhang N, Deng B, Zhang Y, et al. Radiotherapy alone versus concurrent chemoradiotherapy in intermediate risk nasopharyngeal carcinoma: A multicentre, open-label, noninferiority, randomised phase III trial. J Clin Oncol. 2022;40(16):6000–6000. https://doi.org/10.1200/JCO.2022.40.16_suppl.6000.CrossRef

Title: Weekly versus triweekly cisplatin treatment in patients with locally advanced nasopharyngeal cancer during concurrent chemoradiotherapy
Authors: Xin Li
Lei Li
Ruimei Sun
Jingyan Gao
Zhengfei Li
Yongyuan Xue
Lixiu Zhu
Tianrui Xu
Chuanzheng Sun
Yan Xi
Wei Xiong
Publication date: 01-12-2023
Publisher: BioMed Central
Keyword: Radiotherapy
Published in: European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-023-01297-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Weekly versus triweekly cisplatin treatment in patients with locally advanced nasopharyngeal cancer during concurrent chemoradiotherapy

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Global trends and hotspots in research on acupuncture for stroke: a bibliometric and visualization analysis

Prevalence of oral complications in the course of severe SARS-CoV-2 infection under mechanical non-invasive ventilation

A simple scoring system for the prediction of early pregnancy loss developed by following 13,977 infertile patients after in vitro fertilization

Comparison of telemonitoring combined with intensive patient support with standard care in patients with chronic cardiovascular disease - a randomized clinical trial

Identification of ANXA3 as a biomarker associated with pyroptosis in ischemic stroke

The effect of frontal trauma on the edentulous mandible with four different interforaminal implant-prosthodontic anchoring configurations. A 3D finite element analysis